Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Axsome’s portfolio includes FDA-approved treatments for major depressive disorder, narcolepsy, obstructive sleep apnea, and migraine. The company, currently valued at $6.12 billion, is also ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Based on the feedback from the FDA, the Company’s regulatory data package would be sufficient for the submission of an sNDA for AXS-05 for the treatment of Alzheimer’s disease agitation. Axsome ...

Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Axsome Therapeutics, Inc. (NASDAQ ... Another major catalyst was the FDA approval of SYMBRAVO for the acute treatment of migraine with or without aura in adults. This was announced in early ...

Axsome anticipates submitting the planned sNDA ... associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range ...

TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics ...